Why invest in THERAtRAME
A new vision in cancer research
THERAtRAME is pioneering a first-in-class approach targeting tRNA epitranscriptomics to address the largest untreated segment in oncology. By overcoming tumor plasticity and immune resistance, we unlock a mutation-agnostic therapeutic strategy applicable across solid tumors.
We convert unmet need into first-in-class opportunity.
Investment Plan
Investment Opportunity
THERAtRAME is raising a Series A to rapidly achieve clinical proof-of-concept and generate an acquisition-ready dataset in immune-refractory oncology. This is supported by a differentiated dual mechanism (tumor killing + antigen-driven immune activation), a scalable platform, and a biomarker-driven strategy focused on high unmet-need populations. With no direct competition at the target level and strong alignment with pharma demand for first-in-class assets, the company is positioned for early value inflection and high-value partnership opportunities.
Our Investors
They trust us to build the future of cancer research.
Invest in THERAtRAME !
We turn unmet need into first-in-class opportunity.